SCYNEXIS Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of SCYNEXIS Inc in the market are various pharmaceutical companies that specialize in the development of antifungal drugs. Some notable competitors include Pfizer Inc, Merck & Co. Inc, Novartis AG, and Johnson & Johnson. These companies also focus on researching and producing solutions for fungal infections. SCYNEXIS Inc competes in this dynamic market by leveraging its innovative antifungal portfolio, unique research approaches, and commitment to bridging unmet medical needs. By actively participating in the competitive landscape, SCYNEXIS Inc continues to ensure that patients have access to effective antifungal treatments.

SCYNEXIS Inc is a biotechnology company based in New Jersey, United States. Established in 1999, it specializes in the research and development of novel anti-infectives, including antifungal therapies. The company focuses on delivering innovative solutions to combat serious and life-threatening fungal infections. With a team of experienced scientists and a strong commitment to scientific excellence, SCYNEXIS Inc has made significant advancements in the field of antifungal drug discovery. By leveraging its proprietary platform technologies, the company aims to address the unmet medical needs in the fight against fungal infections and improve patient outcomes worldwide.

SCYNEXIS Inc has achieved several significant milestones. Firstly, the company successfully developed and obtained FDA approval for its revolutionary antifungal drug, ibrexafungerp, which marks a major breakthrough in the treatment of various fungal infections. SCYNEXIS Inc also formed multiple strategic partnerships and collaborations with leading pharmaceutical firms to further advance the research and development of their pipeline products. Additionally, the company has demonstrated strong clinical trial results and gained recognition within the industry for its innovative approach. These milestones solidify SCYNEXIS Inc's position as a key player in the pharmaceutical sector, with a promising future ahead.

SCYNEXIS Inc is primarily present in the United States.

SCYNEXIS Inc is a biotechnology company focused on developing and commercializing innovative therapies for serious and life-threatening fungal infections. Their corporate philosophy revolves around delivering novel solutions to patients in need, ensuring scientific excellence, and maintaining a strong commitment to integrity and accountability. With a vision to transform the treatment landscape, SCYNEXIS Inc values scientific innovation, patient-centricity, collaboration, and continuous improvement. By leveraging their expertise and cutting-edge research, SCYNEXIS Inc strives to provide effective therapies that improve patient outcomes and address critical unmet medical needs in the field of antifungal therapies.

Analysts currently set an average price target of 3,74 USD for the SCYNEXIS stock (median: 4,08 USD), implying -27,8 % versus the latest price. The consensus is based on 9 analyst ratings.

SCYNEXIS Koersdoelstellingen analisten 2026

9 analysts currently rate the SCYNEXIS stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect SCYNEXIS to generate revenue of 39,19 Miljoen USD and earnings per share of -0,05 USD.

SCYNEXIS Koersdoelstellingen analisten 2026

Converted at the current exchange rate, the SCYNEXIS share trades at 4,42 EUR (5,12 USD).

The SCYNEXIS share (SCYX) is listed on 4 stock exchanges, including: NASDAQ (SCYX), Frankfurt (135A.F), München (135A.MU), London (0L49.L).

SCYNEXIS Inc is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of infectious diseases and other conditions. The company is headquartered in Jersey City, New Jersey, and also has offices in North Carolina and Massachusetts. SCYNEXIS has three main business areas: research and development, licensing and strategic partnerships, and commercialization of products. In its research and development department, the company uses advanced technologies and innovative approaches to identify, develop, and test new chemical compounds and drug candidates. These drug candidates target serious infectious diseases such as vaginal candidiasis, aspergillosis, and systemic fungal infections, which can potentially be life-threatening. Due to the high development costs and long development times, SCYNEXIS also collaborates with strategic partners to accelerate the development of its product candidates and minimize risk. The company's key partners include leading players in the pharmaceutical industry such as Pfizer and Roche. Another important branch of SCYNEXIS is the licensing of its technologies and product candidates to third parties. Through this licensing, the company aims to monetize its technologies without bearing the high costs of regulatory approval and marketing. Previous licensees of SCYNEXIS include companies such as Allergan and Sanofi. Recently, SCYNEXIS has also started to commercialize its own products. In 2018, the company received approval from the US Food and Drug Administration (FDA) for its first commercial product, Brexafemme® (Ibrexafungerp), an oral medication for the treatment of vaginal candidiasis. Overall, SCYNEXIS focuses on developing products with high medical needs that can also be commercially successful. The company has a strong pipeline of drug candidates that can potentially be life-saving, and it is well positioned to benefit from the growing demand for innovative therapies in the global healthcare industry. The company relies on close collaboration with partners and licensees to minimize risk and accelerate the development of its medications. By commercializing its own products like Brexafemme®, the company has already demonstrated its ability to successfully bring innovative therapies to market and generate long-term growth. Overall, SCYNEXIS' business model is focused on developing innovative therapies and cooperating with partners and licensees to minimize risk and increase the market success of its products. The company is well positioned to benefit from the growing demand for innovative medications in the global healthcare industry and to realize its vision of improving patients' lives through innovative therapies.

De verwachte omzet van SCYNEXIS bedraagt 39,19 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van SCYNEXIS bedraagt -2,43 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van SCYNEXIS bedraagt momenteel -102,39. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het SCYNEXIS-aandeel in te schatten.

De koers-omzetverhouding (P/S) van SCYNEXIS bedraagt momenteel 6,34. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het SCYNEXIS-aandeel.

De Eulerpool Kwaliteitsscore voor SCYNEXIS is 2/10.

De ISIN van SCYNEXIS is US8112922005. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van SCYNEXIS is A2P9T4. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van SCYNEXIS is SCYX. Onder dit beurstickersymbool wordt het SCYNEXIS-aandeel op de beurs verhandeld.

SCYNEXIS betaalde de afgelopen 0 jaar elk jaar dividend.

SCYNEXIS wordt toegewezen aan de sector 'Gezondheid'.

De dividenden van SCYNEXIS worden in USD uitgekeerd.